NEW YORK (GenomeWeb) – Investigators are making a case to colleagues in the precision oncology field that their findings in a recent study — showing colorectal cancer patients with HER2 amplification have poor responses to EGFR targeted therapy — should be taken into consideration in clinical practice and could help improve patient care.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.